| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/21/2005 | US20050085495 Reacting with acry bromide compound; activation withphosphonacetic acid compound; antitumor agents |
| 04/21/2005 | US20050085494 Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| 04/21/2005 | US20050085493 Quinazolinone derivatives and their use as cb agonists |
| 04/21/2005 | US20050085492 Glycinamide ribonucleotide formyl transferase inhibitor |
| 04/21/2005 | US20050085491 Novel crystalline forms of valacyclovir hydrochloride |
| 04/21/2005 | US20050085490 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| 04/21/2005 | US20050085489 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 04/21/2005 | US20050085487 Heterocyclic compounds |
| 04/21/2005 | US20050085486 Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
| 04/21/2005 | US20050085485 Parkinson's disease; mixing with lactose and starches |
| 04/21/2005 | US20050085484 Anticancer agents, particluarly mammary glands, rectums; endometriosis; |
| 04/21/2005 | US20050085482 Anticancer agents |
| 04/21/2005 | US20050085481 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands |
| 04/21/2005 | US20050085480 Water-soluble phenylpyridazine compounds and compositions containing the same |
| 04/21/2005 | US20050085479 Synergistic mixture |
| 04/21/2005 | US20050085478 Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
| 04/21/2005 | US20050085477 Antitumor agents; synergistic mixture |
| 04/21/2005 | US20050085476 Polymerase inhibitors; antiischemic agents; brain disorders; cardiovascular disorders; antiinflammatory agents; antiarthritic agents; neurodegenerative agents; Alzheimer's disease; muscular disorders; antidiabetic agents; kidney disorders; viricides; anticancer agents; immunosuppressants |
| 04/21/2005 | US20050085472 Pyrazolo pyrimidine derivatives and methods of use thereof |
| 04/21/2005 | US20050085471 Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents |
| 04/21/2005 | US20050085470 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators |
| 04/21/2005 | US20050085469 Fused bicyclic pyrimidine derivatives |
| 04/21/2005 | US20050085468 Substituted quinobenzoxazine analogs |
| 04/21/2005 | US20050085467 Androgen receptor antagonists |
| 04/21/2005 | US20050085466 such as 1-[4-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-ylmethyl)benzenesulfonyl]-piperidine-3-carboxylic acid ethyl ester; for treatment of acne, alopecia, and oily skin; kits |
| 04/21/2005 | US20050085465 Quinazoline compounds |
| 04/21/2005 | US20050085464 Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human |
| 04/21/2005 | US20050085463 Administering an amount of N-desmethylclozapine to subject which is thereapeutically effective in improving the cognition of subject |
| 04/21/2005 | US20050085462 Solid oral formulation coated with hydroxypropyl methylcellulose; the polymer coating is free of polyethylene glycol |
| 04/21/2005 | US20050085461 Benzenesulfonamide derivatives |
| 04/21/2005 | US20050085460 useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease |
| 04/21/2005 | US20050085458 Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
| 04/21/2005 | US20050085457 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 04/21/2005 | US20050085456 Compounds useful in therapy |
| 04/21/2005 | US20050085454 Prevention, management of diabetes in humans, primates; plant extracts |
| 04/21/2005 | US20050085453 Methods for the treatment of endometriosis |
| 04/21/2005 | US20050085452 Epoxidation using hydrogen peroxide of 16-dehydropregnanolone acetate ; reduction using hydrazine hydrate; oxidation |
| 04/21/2005 | US20050085451 Interference with absorption of cholesterol using synergistic mixture of fatty acid and sterol ; side effect reduction |
| 04/21/2005 | US20050085450 Oral antidepressant formulation |
| 04/21/2005 | US20050085449 Antidepressants; sexual disorders; osteoporosis; alopecia; anemia; benign prostate hyperplasia; anticancer agents |
| 04/21/2005 | US20050085448 Viricides against herpes virus; autoimmune disease; antitumor agents |
| 04/21/2005 | US20050085446 bactericial composition for topical application to the eye containing a soluble polymer to reduce the precipitation of the bactericide on the cornea; particularly a fluoroquinolone, a steroidal or non-steroidal anti-inflammatory agent, cyclodextrin, a hydroxy acid and water with a pH between 4.5 and 7. |
| 04/21/2005 | US20050085445 Mixture containing hydrophilic additive; measured dosage aerosol inhaler |
| 04/21/2005 | US20050085444 Cosmetic or dermatological use of vitamin a or the esters thereof in combination with a partly methylated beta-cyclodextrin |
| 04/21/2005 | US20050085443 Composition and method for treating bezoar and trichobezoar |
| 04/21/2005 | US20050085442 Use of mannan from saccharomyces cerevisiae for the treatment of asthma |
| 04/21/2005 | US20050085441 Use of soluble monovalent oligosaccharides as inhibitors of HIV-1 fusion and replication |
| 04/21/2005 | US20050085440 Formulation |
| 04/21/2005 | US20050085439 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof |
| 04/21/2005 | US20050085438 particularly oral, transdermal or transmucosal administration of capecitabine for treatment of psoriasis |
| 04/21/2005 | US20050085437 Crystalline drug form |
| 04/21/2005 | US20050085434 Ballast administering to human skins; dna vaccine; high density core overcoated with amorphous reservoir containing dna |
| 04/21/2005 | US20050085432 Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
| 04/21/2005 | US20050085431 Treatment of hypertension |
| 04/21/2005 | US20050085430 Phosphodiesterase-4 (PDE4) inhibitor such as roflumilast or cilomilast; low amounts of active agents, less prone to detrimental side effects |
| 04/21/2005 | US20050085429 Administering folinic acid; anxiolytic agents; premenstrual tension; repiratory system disorders; asthma; eating disorders% |
| 04/21/2005 | US20050085428 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease |
| 04/21/2005 | US20050085427 Transfection agents |
| 04/21/2005 | US20050085425 Novel peptidomimetic NS3-serine protease inhibitors of hepatitis C virus |
| 04/21/2005 | US20050085423 Administering an amide ciompound ; analgesics; antiinflamamtory agents |
| 04/21/2005 | US20050085415 Nanoparticles injected directly into eye; integrin receptor antagonist; angiogenesis inhibitor, polypeptide |
| 04/21/2005 | US20050085414 Novel medical use for tachykinin antagonists |
| 04/21/2005 | US20050085408 Drugs ameliorating hypo-hdl cholesterolemia |
| 04/21/2005 | US20050084918 Method for the identification of agents that inhibit or promote cataracts and uses thereof |
| 04/21/2005 | US20050084897 DNA encoding human vanilloid receptor VR3 |
| 04/21/2005 | US20050084860 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 04/21/2005 | US20050084835 Karaoke system with built-in camera |
| 04/21/2005 | US20050084553 Composition containing moutan root bark extract as active ingredient |
| 04/21/2005 | US20050084548 Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient |
| 04/21/2005 | US20050084547 sclareolide, a sclareolide-like compound, sclareol, a sclareol-like compound; cytotoxic to cancerous cells |
| 04/21/2005 | US20050084530 Rapid acting freeze dried oral pharmaceutical composition for treating migraine |
| 04/21/2005 | US20050084529 Oral bioavailability; protease inhibitors with water soluble polymer and surfactant |
| 04/21/2005 | US20050084528 Anticoagulants comprising a synergistic mixture of nimesulide and a subtherapeutical dose of aspirin; broad spectrum of activity (i.e. activity against a wider range of agonists) with fewer side effects; typical dosage:10 mg. aspirin/12.5 mg nimesulide; admininstered orally concurrently or sequentially |
| 04/21/2005 | US20050084527 Pharmaceutical formulations containing combinations of epinastine, pseudoephedrine, and methylephedrine |
| 04/21/2005 | US20050084524 Method for potentiating activity of a chemotherapeutic drug |
| 04/21/2005 | US20050084523 Inhaling formulation providing analgesia to patient; contains one rapid-onset opioid and a sustained-effect opioid; avoiding toxicity while achieving analgesia, side effect occurs before the onset of toxicity; dispensers |
| 04/21/2005 | US20050084521 A non-aqueous adhesive layer on a side of the support and comprising an adhesive and a vaporizable antimicrobial agent; antimicrobial adhesive sheet has a moisture permeability of at least 1,000 g/m2*24 hrs; exerts the antimicrobial activity not only on an attached site but also in the space by the site |
| 04/21/2005 | US20050084520 Method for providing long-lasting pain diminishment through topical or intranasal administration of civamide |
| 04/21/2005 | US20050084518 For producing beautiful skin and improving constipation, reducing hair loss |
| 04/21/2005 | US20050084516 Process for making gel films |
| 04/21/2005 | US20050084509 Use of citric acid and low concentrations of alpha-hydroxy acids for superficial skin treatment |
| 04/21/2005 | US20050084505 Utilization of ubiquinones for influencing the effect of histamine |
| 04/21/2005 | US20050084501 Therapeutic agent for a cancer and method of screening the same, and health-care auxillary food |
| 04/21/2005 | US20050084490 Boroproline compound combination therapy |
| 04/21/2005 | US20050084489 Synergistic administration of Vitaxin, a FAB fragment, or a competitive binding antibody for binding integrin alpha V beta 3 with the enzyme inhibitor; antiinflammatory, anticarcinogenic agents; autoimmune and metabolic bone disorders |
| 04/21/2005 | US20050084476 Orally administering phosphate ion absorbent comprising as an active ingredient a weakly basic anion exchange resin, wherein resin is a copolymer containing as monomer components divinylbenzene and acrylamide or divinylbenzene and acrylate, wherein the copolymer further contains a tertiary amino group |
| 04/21/2005 | US20050084463 Antiinflammatory, antiarthritic agents, analgesics for pain caused by diabetic assoicated conditions, pneumoconiosis, angina, menstruation or cancer |
| 04/21/2005 | US20050084459 Hydroxocobalamin as an active agent for preventing tobacco smoke-associated loss of peroxidase activity in the aerodigestive |
| 04/21/2005 | US20050084458 Solution or dispersion of lipophilic dialkyl diselenide such as dihexyl diselenide in a carrier for topical use |
| 04/21/2005 | US20050084457 Capsules for inhalation made from specific capsule materials such as a mixture of cellulose derivatives, starch, starch derivatives, chitosan and synthetic plastics, reduced moisture content, containing tiotropium salt in the form of powdered preparations; stability |
| 04/21/2005 | US20050084455 Two anti-tuberculosis drugs, and a biodegradable polymer such as polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymer, polycaprolactone, polysebacic anhydride in dosage form |
| 04/21/2005 | US20050084454 A quaternary ammonium salt as an active agent and a pharmaceutically acceptable carrier suitable for intranasal delivery, formulated to reduce odors without triggering non-allergic rhinitis when delivered intranasally |
| 04/21/2005 | CA2824210A1 Absorbable implants and methods for their use in hemostasis and for the treatment of osseous defects |
| 04/21/2005 | CA2785138A1 Rapidly disintegrating formulation |
| 04/21/2005 | CA2578473A1 Peptide nucleic acid conjugates and uses thereof |
| 04/21/2005 | CA2559836A1 Thermogenic and fiber containing weight-loss supplement |
| 04/21/2005 | CA2549931A1 Use of l-butylphthalide in the manufacture of medicaments for prevention and treatment of cerebral infarct |
| 04/21/2005 | CA2548578A1 Composition for treatment of osteoarthritis containing apigenin as chondroregenerative agent |
| 04/21/2005 | CA2546730A1 A method for the treatment of malignant diseases by inhibiting nucleolin |
| 04/21/2005 | CA2544733A1 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |